ALPHARMA, Inc. (NY:ALO)
36.94
-0 (-0%)
| ALPHARMA, Inc. (NY:ALO) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $36.94 | 52 Week High | $38.14 | ||
| Open | $36.94 | 52 Week Low | $21.27 | ||
| Day High | $36.94 | P/E | N/A | ||
| Day Low | $36.94 | EPS | $-2.06 | ||
| Volume | 6,400 | ||||
| More ALO Info: Chart SEC Filings Profile Historical Options | |||||
Alpharma Summary
Alpharma, Inc. develops, manufactures, and markets pharmaceutical products for humans and animals. The company has three business lines: Pharmaceuticals, Active Pharmaceutical Ingredients (API), and Animal Health (AH).
Executives
Dean Mitchell - CEO, President, Director
Links
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| KG | 8 | JNJ | 4 |
| OMRI | 4 | KG | 3 |
| MSFT | 2 | TTWO | 2 |
| NRG | 2 | SCRX | 2 |
| DSL | 2 | ABI | 2 |
| BRL | 2 | CPN | 2 |
Entities who have mentioned ALO
- Banc of America | View Related Stories »
- Cowen & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Lehman Brothers | View Related Stories »
- Jefferies & Co | View Related Stories »
- Matrix USA | View Related Stories »
- Roth Capital | View Related Stories »
- Merriman Curhan Ford | View Related Stories »
- Citi | View Related Stories »
- Merrill Lynch | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Bankruptcy | View Related Stories »
- Goldman Sachs | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- Apollo Management | View Related Stories »
- RBC Capital | View Related Stories »
- Aurora Capital Group | View Related Stories »
- Daniel Loeb | View Related Stories »
- UBS | View Related Stories »
- Morgan Stanley | View Related Stories »
- Robert W Baird | View Related Stories »
- BMO Capital | View Related Stories »
- Friedman, Billings, Ramsey | View Related Stories »
- Crude Oil | View Related Stories »
- Standard & Poor's | View Related Stories »
View All ReportsStreetInsider.com Reports on ALO
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- King Pharmaceuticals (KG) Completes Acquisition of Alpharma
- S&P Announces Changes to US Indices: IRM for UST, FSP for ALO
- Notable Analyst Rating Changes 12/03: LMT, DRI, CTAS Upgraded; ALO, SYK, FSLR Downgraded
View All Press ReleasesCompany Press Releases on ALO
- American Electric Power Awards Alstom Power Contracts Worth Over USD 100 Million (EUR70 Million) to Add Power and Reliability to Its DC Cook 1 and Conesville 4 Power Plants in the US
- Alstom and Schlumberger Seal a Joint Agreement to Develop Carbon Capture & Storage Readiness Studies For Power Plants
- Video: AEP and Alstom Commission First of Its Kind Carbon Capture and Sequestration (CCS) Project
- Pilot Project Captures 90% of CO2
StreetInsider Reports on ALO by Category
View All BlogsBlogs on ALO
- Eric Mindich's Eton Park Capital Likes Gold
- Updated FDA Decision Calendar: Five Decisions Before Year-End
- Hedge Fund Tracking: Eton Park Capital (Eric Mindich), Q3 2008
- Updated FDA Calendar: Cypress Bioscience Looks Like a Buy
- Full FDA Calendar for Remainder 2008
Comments on recent ALO articles
Comments on ALO
No comments are currently available.
on Jan 2, 2009
at 03:04 PM Despite Lehman failure... Hats off to the Wall Street gurus who pulled off deals despite the carnage for example Teva's successful takeover of Barr was represented by Lehman until the venerable finance house went belly up. Nevertheless the deal close on time.
Article: Top 15 For 2008 (No. 14): M&A Wreckage